Table 3 Clinical outcomes of patients receiving ENMD-2076.

From: A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)

Median number of cycles (range)

2 (1–10)

≥6-month PFS (%)

20.8% (95% CI: 3.2–38.4)

Best Responsea; N (%)

PRb

2 (9%)

SDc

8 (35%)

PD

13 (56%)

ORR (%)

CR + PR

9% (95% CI: 1.55–33.23)

CBR (%)

CR + PR + SD ≥6 months

17% (95% CI: 3.08–20.46)

Median OS

14.1 months (95% CI 6.07–20.07)

Median PFS

2.5 months (95% CI 2.20–4.47)

  1. a23 of 25 patients were evaluable for response.
  2. bTissue types with PR were, angiosarcoma and undifferentiated pleomorphic sarcoma.
  3. cTissue types with SD ≥6-months were, leiomyosarcoma and malignant peripheral nerve sheath tumor (MPNST).
  4. Abbreviations – PFS, progression free survival; PR, partial response; SD, stable disease; PD, progression of disease; ORR, Overall Response Rate; CBR, Clinical Benefit rate; OS, overall survival.
Back to article page